The IBRI is an independent institute for applied scientific research enabling the bioscience industry and key academic research partners to collaborate on projects and sponsor research to improve human health and nutrition.

What

  • The Indiana Biosciences Research Institute (IBRI) is a 501(c)(3) not-for-profit and independent applied research institute formed in 2013 and initially funded by the state of Indiana, the state’s leading life sciences companies, research universities, and the philanthropic community.
  • Founding partners were the state of Indiana, Lilly Endowment, Eli Lilly and Company Foundation, Roche Diagnostics, Dow AgroSciences, Indiana University Health, Indiana University and Cook Medical.

Why

  • Indiana’s life sciences economy comprises 1,689 companies employing 55,000 with $90,000+ annual salaries and has a $78 billion-dollar annual economic impact to the state.
  • In 2012, Indiana state, civic, corporate and academic leaders called for creating an independent applied research institute to serve as a novel, mutually beneficial bridge between industry and academia. The goal is to capture and accelerate game-changing, outcome-driven research—both industry-sponsored and publicly funded—through the attraction and retention of world-class talent to IBRI.
  • IBRI exists to bring together companies and universities to work collaboratively on interrelated health issues that are of both global significance and have a disproportionate impact on Hoosiers—cardiovascular disease, diabetes, obesity and poor nutrition, as well as related health data analytics.

Where

  • IBRI is currently housed in 18,000-square feet of leased lab and office space in the Indiana University School of Medicine’s Biotechnology Research and Training Center at 1345 W. 16th Street on Indianapolis’ near west side on the border of the planned 16 Tech Innovation Community.
  • With groundbreaking scheduled for fall 2018, IBRI plans to anchor the new 16 Tech Innovation Community with 60,000 square feet of office, innovation, collaboration and lab space; completion is scheduled for mid-2020.
  • 16 Tech is purpose-built to develop, attract and retain world-leading talent to collaborate, create and commercialize new ideas across a spectrum of advanced industries, including life sciences, technology, advanced engineering, data science and other technology-intensive industries.

Who

  • IBRI employs 29 full-time scientific and administrative employees and a dozen students and interns for its research teams.
  • Current IBRI leadership includes:
    • Prof. Prof. Dr. Rainer Fischer, Chief Executive Officer, Chief Scientific and Innovation Officer
    • Jay McGill, Ph.D., Chief Operating Officer ­
    • Stephanie Grinage, Vice President for Advancement ­
    • Mark Andersen, CPA, CFA, Chief Financial Officer, Vice President of Administration ­
    • Vidadi Yusibov, Ph.D., Senior Research Fellow and Research Program Director ­
    • Michael Pugia, Ph.D., Research Fellow, Director of the Single Cell Analytics Center ­
    • Daniel Robertson, Ph.D., Research Fellow, Director of the Applied Data Sciences Center and Vice President of Digital Technology ­
    • Teresa Mastracci, Ph.D., Senior Scientist, Director of the Regenerative Medicine and Metabolic Biology Center

When

  • By attracting new and retaining existing talent, IBRI’s goal over the next five years is to build a world-class organization of researchers, innovators, and entrepreneurs that will catalyze scientific discovery and its application, resulting in improved health and nutrition outcomes for patients and consumers.

How

  • IBRI was initially funded with $50 million provided by the State of Indiana, Lilly Endowment, Eli Lilly and Company, Roche Diagnostics, Dow AgroSciences, IU Health and Indiana University.
  • In 2016, the institute received an additional $88.7 million in funding commitments from Lilly Endowment, the Eli Lilly and Company Foundation and Cook Medical.
  • In 2016, Teresa Mastracci received a five-year grant totaling $750,000 from the JDRF for projects related to type-1 diabetes.
  • In 2017 the institute received an additional $20 million commitment from the State of Indiana to accelerate its build-out and continue growth.
  • IBRI is looking to expand its partnerships with life sciences and IT companies and philanthropic organizations worldwide to increase the potential for research, discovery, translation, and collaboration. Learn more about donation opportunities.

Governance

  • The Board of Directors supervises the IBRI management structure. There are currently 11 members, including a representative of the State of Indiana, the CEO of the IBRI, and other high-level members representing the life sciences industry, research institutions, investors, donor organizations and regional universities.
  • The Scientific Advisory Board provides guidance on the direction and implementation of research and development. There are currently 11 members including the Chief Executive Officer/Chief Innovative and Scientific Officer (CEO/CSIO).
  • The Leadership Team is responsible for the day-to-day operations of the IBRI and is comprised of the CEO/CSIO, COO and CFO and is supported by four scientific principal investigators.

Media Contact
Mark Craft
Executive Director of Engagement, Communications and External Affairs
Office: 317-983-3313
Mobile: 317-670-2270
mcraft@indianabiosciences.org